10-K: Cryo-Cell Reports Net Loss Amid Duke License Dispute

Cryo-Cell International, Inc. reported a net loss of $2.43 million for fiscal year 2025, a significant decline from the previous year's profit, primarily due to an impairment charge on public inventory and ongoing litigation with Duke University.

Summary

• Shifted from a net income of $402,095 in fiscal 2024 to a net loss of $2,429,385 in fiscal 2025.
• Total revenue decreased by 1% to $31,566,321 in fiscal 2025 from $31,986,106 in fiscal 2024.
• Processing and storage fees saw a slight decrease, driven by a 12% drop in new domestic cord blood specimens processed, despite a 3% increase in recurring annual storage fee revenue.
• Public cord blood banking revenue significantly decreased to $129,513 in fiscal 2025 from $366,672 in fiscal 2024.
• Incurred a $4,358,834 impairment charge on public inventory in fiscal 2025 due to changes in sales trends and estimated recoverability.
• Research, development, and related engineering expenses decreased substantially to $376,263 in fiscal 2025 from $1,242,536 in fiscal 2024.
• Cash and cash equivalents decreased to $319,031 at November 30, 2025, from $560,960 at November 30, 2024.
• The company is engaged in an arbitration dispute with Duke University, alleging fraudulent inducement and breach of a license agreement, seeking over $100 million in damages. Duke has counterclaimed and issued a termination notice for the license agreement.
• The planned Cryo-Cell Institute for Cellular Therapies and the spinoff of Celle Corp. are on hold due to the Duke dispute.
• The company paid total dividends of $0.40 per share in fiscal 2025 ($0.25 and $0.15 per share).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to the significant net loss, revenue decline, and the major legal dispute with Duke University which has halted key strategic expansion initiatives and resulted in a substantial impairment charge. While some operational aspects show stability, the unresolved litigation and associated uncertainties create considerable downside risk.

Positives

• Recurring annual storage fee revenue increased by 3%.
• Successful dismissal with prejudice of the Lindsey Lehr class action lawsuit.
• Extension of the revolving credit facility maturity date to October 18, 2027, and the term loan maturity date to July 29, 2032.
• Introduction of ExtraVault, a new cold storage service for third-party pharmaceutical companies and medical institutions.
• Reduced Research, Development and Related Engineering Expenses by 69.7% from $1,242,536 in 2024 to $376,263 in 2025.

Negatives

• Shift from net income of $402,095 in fiscal 2024 to a net loss of $2,429,385 in fiscal 2025.
• Overall revenue decreased by 1% year-over-year.
• 12% decrease in new domestic cord blood specimens processed in fiscal 2025.
• Significant decrease in public cord blood banking revenue.
• Incurred a $4,358,834 impairment charge on public inventory in fiscal 2025.
• Cash and cash equivalents decreased by $241,929.
• Net cash from operating activities decreased by $532,304.
• Increased interest expense to $2,066,256 in fiscal 2025 from $1,864,684 in fiscal 2024.
• The Duke License Agreement, a key strategic expansion initiative, has been terminated by Duke, and related projects (Cryo-Cell Institute, Celle Corp. spinoff) are on hold.
• The company is involved in significant arbitration with Duke University, seeking over $100 million in damages, with Duke asserting counterclaims.

Risks

• Common stock may be delisted from NYSE American LLC if continued listing standards are not met.
• May need to raise additional capital, and there is no assurance of obtaining such financing on favorable terms or at all.
• Inability to successfully grow or operate the business, with success dependent on widespread market acceptance of cryopreservation of stem cells.
• Adverse macroeconomic conditions (inflation, slower growth, recession, higher interest rates) could materially adversely affect demand for products and services.
• The industry is subject to rapid technological and therapeutic changes, and future success depends on the continued viability of stem cell use.
• Failure to successfully manufacture mesenchymal stromal cells (MSCs) or negative results in clinical trials for efficacy.
• Clinical development is lengthy and uncertain, with a high rate of attrition for product candidates.
• Product candidates are subject to substantial government regulation, and inability to obtain regulatory approval would negatively impact revenue.
• The stem cell preservation market is increasingly competitive, with some competitors having greater financial resources.
• A failure in the performance of cryopreservation storage facility or systems, or those of Duke, could harm business and reputation.
• Systems and operations are vulnerable to damage or interruption from fire, flood, equipment failure, break-ins, tornadoes, and similar events, without redundant systems or a formal disaster recovery plan.
• Future success depends on the ability to retain key personnel and to attract, retain, and motivate qualified personnel.
• Uncertainty with regard to the outcome of the Duke Arbitration Demand, with potential unfavorable outcomes negatively impacting business, financial position, and results of operations.
• Uncertainty with regard to maximizing shareholder value through the Duke License Agreement, including the proposed spinoff of Celle Corp. and the opening of the Cryo-Cell Institute for Cellular Therapies.
• No assurance of recouping damages related to the Arbitration Demand against Duke or the investment in the Duke License Agreement.
• Failure to obtain and maintain necessary domestic regulatory registrations, approvals, and compliance with ongoing regulations.
• Requirement to spend substantial amounts to comply with legislative and regulatory initiatives relating to patient privacy (HIPAA, HITECH Act).
• Failure to comply with laws related to hazardous materials could result in liability or increased costs.
• International operations are subject to risks, including intellectual property protection, local laws, political/economic conditions, currency fluctuations, and enforcement of contracts.
• Business may be impacted by political events, international trade disputes, war, terrorism, natural disasters, public health issues, industrial accidents, and other business interruptions.
• Information systems are critical, and a failure or significant breach of data security could adversely affect the business and reputation.
• Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.
• Use of open source software may pose particular risks to proprietary software, technologies, products, and services.
• Incur significant costs and demands as a result of operating as a public company, including compliance with Sarbanes-Oxley and NYSE American requirements.
• Failure to maintain an effective system of internal control over financial reporting.
• Increasing scrutiny and changing expectations from investors, customers, and governments with respect to Environmental, Social, and Governance (ESG) policies and practices.
• Principal stockholders and management own a significant percentage (approximately 47%) of voting stock, enabling them to exert significant control.
• May become subject to securities class action litigation, which can be expensive and divert management attention.
• As a smaller reporting company, reduced disclosure and governance requirements may make common stock less attractive to investors.
• Responsible for the indemnification of officers and directors, which could result in substantial expenditures.
• Certain provisions of the charter, bylaws, and Delaware law may delay, defer, or prevent a tender offer or takeover attempt.

Future Outlook

The company anticipates that its cash and cash equivalents, marketable securities, and cash flows from operations, along with external capital, will be sufficient to fund known cash needs for at least the next 12 months. However, the future funding needs for activities related to the Duke License Agreement are unpredictable due to the ongoing arbitration. The company does not anticipate further investments in Duke-related activities until the dispute is resolved, and the opening of the Cryo-Cell Institute for Cellular Therapies and the proposed spinoff of Celle Corp. are on pause with no assurances of when or if they will proceed.

Management Comments

• We intend to maximize our growth potential through our superior quality, value-driven competitive leadership position, product differentiation, an embedded client base, increased public awareness and accelerated market penetration.
• The Company believes that the market for cord blood stem cell preservation is enhanced by global discussion on stem cell research developments and the current focus on reducing prohibitive health care costs.
• The Company believes that the benefits of these provisions [anti-takeover], including increased protection of the potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure the Company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.
• Consistent with its fiduciary duties, the board of directors and management has reviewed and will continue to review strategic options and opportunities for the Company, in order to maximize shareholder value.
• The Company believes Dukes counterclaims are without merit and intends to contest them vigorously.

Industry Context

StockSavvy.ai notes that Cryo-Cell International operates in a rapidly evolving stem cell research and cryopreservation market. The company's focus on umbilical cord blood and tissue stem cell services aligns with broader trends in regenerative medicine, but faces challenges from increasing competition and the need for continuous technological and therapeutic advancements. The dispute with Duke University highlights the complexities and risks associated with collaborative research partnerships and intellectual property in this high-growth, high-regulation sector. The introduction of ExtraVault positions the company to capitalize on the growing demand for third-party cold storage services in the biopharmaceutical industry, diversifying its revenue streams beyond direct consumer stem cell banking.

Corporate Governance

Legal Proceedings

• Lindsey Lehr v. Cryo-Cell International, Inc.: A class action complaint filed January 6, 2023, alleging inaccurate advertising. The case was removed to federal court, arbitration was compelled, and class action allegations were dropped. The plaintiff and company filed stipulations to dismiss all claims with prejudice on September 5, 2025. The resolution did not have a material adverse effect.
• Cryo-Cell International, Inc. v. Duke University (Arbitration Demand): Filed October 4, 2024, alleging fraudulent inducement and breach of Patent and Technology License Agreement, seeking over $100 million in damages. Duke responded with counterclaims on November 18, 2024 (amended March 24, 2025) for breach and indemnity. Duke issued a notice of termination of the License Agreement as of May 17, 2025. A final hearing is scheduled for April 2026. The outcome is uncertain and could materially impact the company.

Related Party Transactions

• David Portnoy (Chairman and Co-CEO) and Mark Portnoy (Co-CEO) are brothers.
• Harold Berger (Audit Committee Chairman) provides accounting services to Mark Portnoy and PartnerCommunity, Inc.
• David Portnoy serves as Chairman of the Board of PartnerCommunity, Inc.

Stakeholder Impact

• Shareholders: Negative impact due to net loss, revenue decline, and significant legal dispute with Duke, which has halted strategic expansion plans. Uncertainty regarding the outcome of the arbitration and potential capital raise could affect share price. Dividends were paid, but future sustainability is unclear given the loss.
• Employees: Potential impact on morale and future opportunities due to the pause of the Cryo-Cell Institute and Celle Corp. spinoff, which were intended to create new business units.
• Customers: Continued provision of core cord blood and tissue storage services. The payment warranty for engraftment failure remains in place.
• Creditors (Susser Bank): Celle Corp. became a guarantor under the Credit Agreement, and a Security Agreement was executed for the benefit of lenders, potentially strengthening their position.

Next Steps

• Final hearing on the Company's claims and Duke's counterclaims scheduled for April 2026.
• Company anticipates making discretionary capital expenditures of approximately $1,000,000 over the next twelve months for equipment and software enhancements.
• Company will continue to monitor the Ukrainian-Russian conflict and take action if necessary.
• Company will continue to evaluate and pursue global expansion opportunities on a selective basis.
• Company intends to continue offering cord blood and cord tissue banking services and relying on online advertising and its national team of field cord blood educators.
• Company will continue to review strategic options and opportunities to maximize shareholder value, including mergers, acquisitions, investments, and stock repurchases.
• Company is assessing the impact of ASU 2023-09 (Improvements to Income Tax Disclosures) for fiscal years beginning after December 15, 2024.
• Company is evaluating the impact of ASU No. 2024-03 (Disaggregation of Income Statement Expenses) for annual reporting periods beginning after December 15, 2026.

Key Dates

Recommendation

The company reported a net loss of $2.43 million for fiscal 2025, a significant reversal from the prior year's profit, driven by a substantial impairment charge on public inventory and a 1% decline in overall revenue. The ongoing, high-stakes arbitration with Duke University, including Duke's termination of a key license agreement and the halting of strategic growth initiatives like the Cryo-Cell Institute and Celle Corp. spinoff, introduces considerable uncertainty and risk. While the core storage business shows some recurring revenue stability, the company's future growth prospects are severely clouded by this litigation and the need for potential future capital raises under uncertain terms. The combination of financial underperformance and significant unresolved legal and strategic challenges warrants a 'sell' recommendation for seasoned investors.

Keywords

Cryo-Cell International, CCEL, Stem Cell Banking, Cord Blood Storage, Cord Tissue Storage, Biopharmaceutical, ExtraVault, SEC Filing, 10-K, Financial Report, Arbitration, Duke University, License Agreement, Impairment Charge, Cryopreservation, Cellular Therapy, Regenerative Medicine, Public Banking, Private Banking, NYSE American